CN100337689C - 聚亚烷基二醇酸加合物 - Google Patents

聚亚烷基二醇酸加合物 Download PDF

Info

Publication number
CN100337689C
CN100337689C CNB038175088A CN03817508A CN100337689C CN 100337689 C CN100337689 C CN 100337689C CN B038175088 A CNB038175088 A CN B038175088A CN 03817508 A CN03817508 A CN 03817508A CN 100337689 C CN100337689 C CN 100337689C
Authority
CN
China
Prior art keywords
formula
pag
ester
compound
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038175088A
Other languages
English (en)
Chinese (zh)
Other versions
CN1671422A (zh
Inventor
P·S·拜隆
C-Y·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1671422A publication Critical patent/CN1671422A/zh
Application granted granted Critical
Publication of CN100337689C publication Critical patent/CN100337689C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/337—Polymers modified by chemical after-treatment with organic compounds containing other elements
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038175088A 2002-07-24 2003-07-16 聚亚烷基二醇酸加合物 Expired - Fee Related CN100337689C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39813702P 2002-07-24 2002-07-24
US60/398,137 2002-07-24

Publications (2)

Publication Number Publication Date
CN1671422A CN1671422A (zh) 2005-09-21
CN100337689C true CN100337689C (zh) 2007-09-19

Family

ID=31495718

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038175088A Expired - Fee Related CN100337689C (zh) 2002-07-24 2003-07-16 聚亚烷基二醇酸加合物

Country Status (13)

Country Link
US (2) US7193031B2 (enExample)
EP (1) EP1526872A1 (enExample)
JP (2) JP4451308B2 (enExample)
KR (1) KR100608415B1 (enExample)
CN (1) CN100337689C (enExample)
AR (1) AR040654A1 (enExample)
AU (1) AU2003258518B2 (enExample)
BR (1) BR0313212A (enExample)
CA (1) CA2492775C (enExample)
MX (1) MXPA05000796A (enExample)
PL (1) PL375265A1 (enExample)
RU (1) RU2318004C2 (enExample)
WO (1) WO2004012773A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
JP4451308B2 (ja) * 2002-07-24 2010-04-14 エフ．ホフマン−ラ ロシュ アーゲー ポリアルキレングリコール酸添加剤
WO2005021557A2 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
CA2537113A1 (en) * 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
KR101276422B1 (ko) 2004-03-15 2013-06-19 넥타르 테라퓨틱스 Ｈｉｖ 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트
CA2567630A1 (en) * 2004-05-17 2005-11-24 Mcmaster University Biological molecule-reactive hydrophilic silicone surface
ATE491475T1 (de) * 2004-07-16 2011-01-15 Nektar Therapeutics Konjugate enthaltend gm-csf und ein polymer
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
ATE425204T1 (de) * 2005-08-26 2009-03-15 Novo Nordisk As Verfahren zur modifizierung eines makromolekularen systems
US8133707B2 (en) * 2006-01-17 2012-03-13 Enzon Pharmaceuticals, Inc. Methods of preparing activated polymers having alpha nitrogen groups
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
EP2385843A4 (en) 2009-01-06 2013-02-27 Dyax Corp TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
EP4011917A1 (en) 2010-01-06 2022-06-15 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
US10040761B2 (en) * 2010-06-25 2018-08-07 Nof Corporation Branched hetero polyethylene glycol and intermediate
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
MX358784B (es) 2012-04-03 2018-09-04 Sangart Inc Compuestos de nitroxilo activados con succinimida y metodos para el uso de los mismos para nitroxilacion de proteinas.
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收促红细胞生成素的方法
EP2968597B1 (en) 2013-03-15 2021-08-18 Schindler, William Polyalkylene oxide valerate hemoglobin conjugates
KR20230109785A (ko) 2014-03-27 2023-07-20 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
IL311156A (en) 2015-12-11 2024-04-01 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN113631631B (zh) * 2019-03-29 2023-04-18 日油株式会社 含末端羧基的聚乙二醇的制备方法以及活化聚乙二醇的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670417A (en) * 1985-06-19 1987-06-02 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1995013090A1 (en) * 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
CN1211578A (zh) * 1992-08-26 1999-03-24 霍夫曼-拉罗奇有限公司 聚乙二醇－干扰素结合物
WO2001046291A1 (en) * 1999-12-22 2001-06-28 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
WO2002049673A2 (en) * 2000-12-20 2002-06-27 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5849450B2 (ja) * 1975-07-09 1983-11-04 株式会社日立製作所 スイリヨクシキカプセルユソウソウチノ ボウシクホウ
JP2531661B2 (ja) 1987-02-25 1996-09-04 味の素株式会社 酸素運搬剤
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
PT957929E (pt) * 1996-10-25 2006-06-30 Gilead Sciences Inc Complexos de ligandos de acido nucleico do factor de crescimento endotelial vascular
CN1376164A (zh) 1999-01-29 2002-10-23 霍夫曼-拉罗奇有限公司 Gcsf缀合物
PE20001548A1 (es) 1999-03-02 2001-01-16 Schering Corp Uso de interferon alfa pegilado para el tratamiento de vih-1
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
CN1284603C (zh) 1999-10-08 2006-11-15 内科塔治疗亚拉巴马公司 杂双官能聚乙二醇衍生物和它们的制备方法
US20020065397A1 (en) 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
JP4451308B2 (ja) * 2002-07-24 2010-04-14 エフ．ホフマン−ラ ロシュ アーゲー ポリアルキレングリコール酸添加剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670417A (en) * 1985-06-19 1987-06-02 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
CN1211578A (zh) * 1992-08-26 1999-03-24 霍夫曼-拉罗奇有限公司 聚乙二醇－干扰素结合物
WO1995013090A1 (en) * 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
WO2001046291A1 (en) * 1999-12-22 2001-06-28 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
WO2002049673A2 (en) * 2000-12-20 2002-06-27 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)

Also Published As

Publication number Publication date
PL375265A1 (en) 2005-11-28
US20060167218A1 (en) 2006-07-27
AU2003258518A1 (en) 2004-02-23
JP5112203B2 (ja) 2013-01-09
RU2005105580A (ru) 2006-01-20
US7504477B2 (en) 2009-03-17
KR100608415B1 (ko) 2006-08-02
AU2003258518B2 (en) 2007-01-18
CN1671422A (zh) 2005-09-21
JP2006502250A (ja) 2006-01-19
US20040106747A1 (en) 2004-06-03
JP4451308B2 (ja) 2010-04-14
BR0313212A (pt) 2005-06-28
AR040654A1 (es) 2005-04-13
RU2318004C2 (ru) 2008-02-27
KR20050025663A (ko) 2005-03-14
US7193031B2 (en) 2007-03-20
CA2492775A1 (en) 2004-02-12
MXPA05000796A (es) 2005-04-19
WO2004012773A1 (en) 2004-02-12
CA2492775C (en) 2011-06-21
EP1526872A1 (en) 2005-05-04
JP2009062516A (ja) 2009-03-26

Similar Documents

Publication Publication Date Title
CN100337689C (zh) 聚亚烷基二醇酸加合物
CN1284603C (zh) 杂双官能聚乙二醇衍生物和它们的制备方法
CN1243779C (zh) 具有y形分支的亲水性聚合物衍生物、其制备方法、与药物分子的结合物以及包含该结合物的药物组合物
CN1038035C (zh) 聚乙二醇蛋白质结合物的制备方法
CN1183112C (zh) 聚乙二醇-干扰素结合物
CN1714116A (zh) 经修饰的生物相关物质、其制备方法、及中间体
CN1761473A (zh) 异双官能聚合生物共轭物
CN1771057A (zh) 基于脂肪族生物可降解连接体的可释放的聚合物结合体
CN1280483A (zh) 聚乙二醇－grf偶联物的位点特异性制备
CN1630530A (zh) 聚亚烷基聚合物及其用途
HK1041275B (zh) 刺激巨核細胞生長和分化的組合物及方法
CN1158089A (zh) 聚乙二醇化试剂及由其形成的化合物
CN1732206A (zh) 水解稳定的马来酰亚胺封端的聚合物
CN1434726A (zh) 包含高分子量聚环氧乙烷的多价平台分子
CN1671769A (zh) 聚乙二醇醛衍生物
CN101076353A (zh) 基于脂肪族生物可降解的接头的可释放的聚合物共轭物
EP1507755A2 (en) Novel monofunctional polyethylene glycol aldehydes
US20040122164A1 (en) Novel monofunctional polyethylene glycol aldehydes
CN1108454A (zh) 生物活性化合物
CN1036654C (zh) 抗菌素a40926的酰氨衍生物及其制备方法
CN1671735A (zh) 聚乙二醇化的t1249多肽
HK1078887A (en) Polyethylene glycol aldehyde derivatives
HK1082952A (en) Pegylated t1249 polypeptide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070919

Termination date: 20140716

EXPY Termination of patent right or utility model